According to the Centers for Disease Control and Prevention (CDC), there is no specific antiviral therapy for measles, and management focuses on supportive care to relieve symptoms and address complications. Under physician supervision, vitamin A may be administered to infants and children with measles, particularly in severe cases or hospitalization. If recommended, vitamin A should be given immediately upon diagnosis and repeated the next day, following age-specific doses: 50,000 IU for infants younger than 6 months of age, 100,000 IU for infants 6–11 months of age, and 200,000 IU for children 12 months of age and older. Inappropriate dosing may result in hypervitaminosis A. [1], [2], [3]
According to the Advisory Committee on Immunization Practices (ACIP) of the CDC guidance for the prevention of measles, rubella, and mumps, severely immunocompromised patients exposed to measles should receive intravenous immunoglobulin (IVIG) prophylaxis within 6 days of exposure, regardless of immune or vaccination status, as they may not be protected by the vaccine. This includes those with severe primary immunodeficiency, recent bone marrow transplant (within 12 months of completing immunosuppression or longer with graft-versus-host disease), patients on treatment for acute lymphoblastic leukemia (ALL) or within 6 months of completing chemotherapy, and those with AIDS of advanced HIV (CD4 <15% or <200 cells/mm³ if older than 5 years) who have not received MMR after starting effective antiretroviral therapy. Some experts also include HIB-infected patients without recent confirmation of immune status or measles immunity. For patients already receiving IVIG, a dose of at least 400 mg/kg within 3 weeks before exposure is considered sufficient. For those on subcutaneous IG, at least 200 mg/kg for 2 consecutive weeks before exposure is recommended. [3]
Pregnant women might be at higher risk for severe measles and complications. Thus, IVIG should be administered to pregnant women without evidence of measles immunity who have been exposed to measles. It is recommended to administer IVIG at doses high enough to achieve estimated protective levels of measles antibody titers. In general, for post-exposure prophylaxis of measles, rubella, or mumps, the recommended dose of IG administered intramuscularly is 0.5 mL/kg of body weight (max dose= 15 mL) and the recommended dose of IVIG is 400 mg/kg. [3]
According to recent guidance provided by the CDC and the World Health Organization (WHO), measles treatment is primarily supportive. To help reduce the risk of complications, the WHO recommends that all children and adults with acute measles receive two doses of vitamin A, administered 24 hours apart. The recommended oral dosing is based on age: infants younger than 6 months should receive 50,000 IU once daily for 2 days; those 6 to 11 months old should receive 100,000 IU once daily for 2 days; and children 12 months and older should receive 200,000 IU once daily for 2 days. For children showing clinical signs or symptoms of vitamin A deficiency, a third age-appropriate dose should be administered 2 to 4 weeks after the initial treatment. In general, the guidance notes that measuring vitamin A levels is typically not necessary. No other recommendations specific to adults are noted. [4], [5]
Much of the other literature for treatment of measles is specific to children and pediatric patients. A 2011 Cochrane systematic review evaluated the efficacy of vitamin A supplementation as an adjunctive treatment for measles in children. The investigators conducted a comprehensive search through early 2011 to identify randomized controlled trials enrolling children under the age of 15 years with clinically diagnosed measles who received vitamin A or placebo alongside standard treatment. Eight randomized controlled trials (RCTs; n= 2,574) met eligibility criteria, including both community-based and hospital-based studies conducted in low-income and middle-income countries, with varying baseline population risks and vitamin A formulations. Pooled analyses from these trials demonstrated no statistically significant reduction in overall mortality associated with vitamin A therapy when all studies were included (risk ratio [RR] 0.70; 95% confidence interval [CI] 0.42 to 1.15). However, a predefined subgroup analysis revealed that two consecutive daily doses of 200,000 IU vitamin A significantly reduced measles-associated mortality in children under two years of age (RR 0.21; 95% CI 0.07 to 0.66), particularly in hospitalized settings and regions with case-fatality rates exceeding 10%. Additionally, vitamin A administration was associated with a reduced risk of developing post-measles croup (RR 0.53; 95% CI 0.29 to 0.89), and modest but statistically significant reductions in the duration of pneumonia, diarrhea, and fever were observed. No adverse effects were reported across the studies, and the overall quality of evidence was rated as moderate. These findings suggest that high-dose, two-day vitamin A therapy is effective in reducing measles-related mortality and selected complications in high-risk pediatric populations, particularly in resource-limited healthcare settings. [6]
Due to the lack of specific antiviral treatment for measles, management primarily focuses on supportive care. Available review articles emphasize the importance of preventing dehydration, correcting nutritional deficiencies, and promptly identifying and treating secondary bacterial infections such as pneumonia and otitis media. High-dose vitamin A has been shown to reduce mortality and complications in hospitalized children with measles in developing countries. In the United States, children with measles often have low serum retinol levels, particularly in more severe cases. The American Academy of Pediatrics recommends vitamin A supplementation for all children with severe measles, using age-specific dosing: 200,000 IU for children 12 months and older, 100,000 IU for those 6 to 11 months, and 50,000 IU for infants younger than 6 months; a third dose should be administered 2 to 4 weeks later for children showing signs of vitamin A deficiency. Vitamin A is also recommended for children who are immunosuppressed, have clinical evidence of deficiency, or are recent immigrants from areas with high measles mortality. [7], [8]
A 2010 systematic review assessed the effectiveness of measles vaccination and vitamin A treatment on measles-related morbidity and mortality using data collated for the Lives Saved Tool (LiST). Investigators conducted a comprehensive literature search of publications from 1960 to 2008. A meta-analysis incorporating three RCTs and two quasi-experimental studies concluded that a single dose of measles vaccine conferred 85% effectiveness (95% CI 83 to 87) in preventing measles disease. This estimate was applied as a proxy for measles-specific mortality among children vaccinated before 12 months of age. Serologic data supported higher efficacy when vaccination was administered at older ages, with effectiveness increasing to 95% when the first dose was given at ≥12 months and up to 98% for two-dose regimens. Regarding vitamin A, six high-quality RCTs were analyzed, with overall results showing no significant reduction in measles mortality (RR 0.63; 95% CI 0.37 to 1.08). However, when stratified by dosing regimen, three studies using at least two recommended doses (100,000 to 200,000 IU depending on age) reported a 62% reduction in mortality (RR 0.38; 95% CI 0.18 to 0.81). These findings reinforce WHO strategies incorporating two-dose measles vaccination schedules and standardized vitamin A treatment protocols as critical mortality-reducing interventions in pediatric populations, especially in regions with high measles burden. [9]
A 2020 review discusses the re-emergence of measles and emphasizes the role of vitamin A in the treatment of children and immunocompromised patients. While there are anecdotal reports suggesting that adults may also benefit from vitamin A, the exact dosage for this population is not well-established. However, the authors emphasize that repeated doses of 200,000 IU of vitamin A have shown clinical effects. [10]
A 2012 case series examined the relationship between severe measles, vitamin A deficiency, and the Roma community in Europe. The study focused on six adults from the Roma community in Marseille, France, who had measles and low vitamin A levels, with two of these adults experiencing severe complications. Case patients 1 and 2 were male, aged 21 and 25 years of age, respectively. Case patient 1 developed acute meningoencephalitis and required intensive care, while case patient 2 presented with severe hepatitis and keratitis. Notably, all six patients presented with vitamin A deficiency (0.16 to 0.34 mg/L, reference range: 0.5 to 0.8 mg/L), and two additional Roma individuals without measles also exhibited low vitamin A levels. Vitamin A supplementation was administered to all measles patients following WHO guidelines (200,000 IU intramuscularly; followed by a second dose the next day), and all patients recovered. This case report may demonstrate a potential role for the use of vitamin A deficiency in patients with severe measles complications, particularly in underprivileged populations with limited healthcare access. Overall, the authors concluded that improved vaccination coverage is essential in reducing measles transmission in the Roma community. [11]
According to the 2025 American College of Obstetricians and Gynecologists (ACOG) there is no specific antiviral therapy for measles, and management is supportive. Vitamin A does not prevent or treat measles and is not a substitute for vaccination; it may be used as supportive care only in infants and children with diagnosed measles, while excess preformed vitamin A is contraindicated in pregnancy due to teratogenic risk. For post-exposure prophylaxis, individuals exposed to measles without evidence of immunity should be offered intervention based on pregnancy status and timing. Nonpregnant patients should receive either the MMR vaccine within 72 hours of exposure or immunoglobulin within 6 days, but not both simultaneously. Pregnant patients without immunity should receive IVIG 400 mg/kg within 6 days of exposure. Postpartum patients without evidence of immunity should receive the MMR vaccine within 72 hours of exposure. Infants born to mothers with suspected or confirmed measles should receive IVIG, and when indicated by public health authorities, infants aged 6 to 11 months may receive an early MMR dose followed by routine vaccination per the CDC vaccine schedule. [12]
According to guidance provided by the CDC, those who have been exposed to measles and are unable to demonstrate immunity against the disease should be provided with post-exposure prophylaxis (PEP). To potentially offer protection or alter the clinical course of the disease in vulnerable individuals, they should be administered immunoglobulin (IG) within six days of exposure, or given the MMR vaccination within 72 hours of the initial measles contact. The recommended dose of intramuscular IG is 0.5 mL/kg. The MMR vaccination is rendered ineffective if administered concurrently with IG. [13]
A recent systematic review from 2025 assessed the effectiveness and safety of IG and measles-containing vaccine (MCV) as PEP for susceptible individuals exposed to measles. The review included nine prospective studies conducted across seven countries, evaluating a total of 660 patients who received PEP, comprising 434 individuals administered IG and 226 who received MCV. Studies varied in population, with three exclusively assessing children, one focusing on adults, and five including both children and adults. The analysis highlighted substantial methodological limitations, including incomplete reporting of exposure intensity, time from exposure to treatment, and IG dosing. Furthermore, all included studies were classified as having a moderate or serious risk of bias, primarily due to confounding factors such as the variability in PEP administration timing. Studies that compared PEP recipients to untreated controls demonstrated variable effectiveness, with IG PEP reducing measles infection rates to between 0% and 30%, while MCV PEP showed rates between 0% and 15%. Reported effectiveness estimates ranged from 76% to 100% for IG PEP and 83% to 100% for MCV PEP. However, data on immunocompromised individuals and pregnant women were limited, with only 13 immunocompromised pediatric patients and two pregnant women receiving PEP across all studies. Among the immunocompromised patients, all but one received intravenous IG, except one child who received both intramuscular and intravenous IG, and none contracted measles. However, drawing conclusions on the efficacy of measles PEP in these two populations remains difficult, and further research is warranted. [14]
According to a 2018 article focused on public health responses during measles outbreaks if given to sensitive individuals within six days of the initial exposure, IG has the potential to either protect against the illness or alter its clinical outcome. The suggested range of dosages for intramuscular IG (IGIM) administration is between 0.2 and 0.5 mL/kg of body weight. Given that the highest amount advised for IGIM is 15 mL, older children or adults who weigh more than 30 kg may receive less protection from IGIM. U.S. recommendations propose intravenous administration of IG to severely immunocompromised individuals and vulnerable pregnant women exposed to measles, partly because of these volume limits. A 400 mg/kg body weight dosage of IGIV is advised. Notably, individuals who are already on subcutaneous immunoglobulin (IGSC) or IVIG therapy are protected if, respectively, at least 200 mg/kg body weight was given for two weeks in a row and 400 mg/kg body weight was given within three weeks before to measles exposure. [15]
A 2021 outbreak investigation evaluated the evidence for measles PEP, with a specific focus on IVIG, in infants exposed during a measles outbreak in Austria. In this study, 400 mg/kg IVIG (IgVena®, Kedrion) was administered as PEP to 63 of 65 eligible infants, primarily those younger than 6 months of age or those without timely or protective measles-specific maternal IgG antibody levels; two infants whose parents declined IVIG served as comparators. None of the infants who received IVIG developed measles or symptoms suggestive of measles, whereas both infants who did not receive PEP developed laboratory-confirmed measles, resulting in a calculated effectiveness of 99.2 to 99.3% depending on follow-up assumptions. Safety monitoring identified no serious adverse events, with only two cases of transient, self-limiting fever reported after discharge. Laboratory evaluation of four IVIG batches demonstrated measles virus–neutralizing antibody geometric mean titers of 10.0 to 12.7 IU/mL (200 to 254 IU/g), corresponding to estimated post-infusion serum levels 1.57 to 2.26 times higher than the postulated minimum protective threshold for up to four weeks. The findings provide contemporaneous clinical and laboratory evidence supporting the effectiveness and safety of IVIG at a dose of 400 mg/kg for measles PEP in infants, and document that current IVIG preparations retain sufficient measles-neutralizing antibody activity despite changes in donor immunity profiles. [16]